xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06000137</url>
    </required_header>
    <id_info>
      <org_study_id>dezocine and sufentanil</org_study_id>
      <nct_id>NCT06000137</nct_id>
    </id_info>
    <brief_title>The Comparison of the Analgesic Effects of Dezocine and Sufentanil in Patient-controlled Analgesia After Laryngectomy</brief_title>
    <official_title>The Comparison of the Analgesic Effects of Dezocine and Sufentanil in Patient-controlled Analgesia After Laryngectomy</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Eye &amp; ENT Hospital of Fudan University</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Eye &amp; ENT Hospital of Fudan University</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        Laryngeal cancer is one of the most common tumors in otolaryngology. In China, it accounts&#xD;
        for 1-5% of all malignancies and has an incidence of 1.13 per 100,000. Surgical resection is&#xD;
        the most important treatment for patients who are not candidates for chemoradiotherapy or&#xD;
        refuse chemoradiotherapy. The types of surgery include total and partial laryngectomy.&#xD;
        Patients with laryngeal cancer often face multiple physical and psychiatric changes after&#xD;
        surgery, such as daily large sputum production accompanied by cough, cleaning care of the air&#xD;
        incision, fatigue, and sleep disturbances. Some patients do not actively exclude secretions&#xD;
        due to pain, and the formation of sputum plugs causes lung inflammation, which is not&#xD;
        conducive to postoperative recovery. Good postoperative pain management is beneficial to&#xD;
        shorten the length of hospital stay and reduce mortality. Sufentanil is most commonly used&#xD;
        for postoperative analgesia and has good analgesic effect, but there are some adverse&#xD;
        effects, such as dizziness, nausea and vomiting, urinary retention, skin itching, respiratory&#xD;
        depression, etc. As a new type of analgesic, dezocine has been widely used in clinical&#xD;
        practice with few adverse reactions to the respiratory and circulatory system, and its&#xD;
        application to postoperative analgesia can significantly improve the immune activity. At&#xD;
        present, there are not many studies on continuous analgesia of dezocine, mostly single-dose&#xD;
        analgesia studies, this study for different doses of dezocine for the postoperative analgesic&#xD;
        effect of laryngeal cancer patients, compared with the current classic opioid analgesics, to&#xD;
        provide a new scheme for clinical medication.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Laryngeal cancer is one of the most common tumors in otolaryngology. In China, it accounts&#xD;
        for 1-5% of all malignancies and has an incidence of 1.13 per 100,000. Surgical resection is&#xD;
        the most important treatment for patients who are not candidates for chemoradiotherapy or&#xD;
        refuse chemoradiotherapy. The types of surgery include total and partial laryngectomy.&#xD;
        Patients with laryngeal cancer often face multiple physical and psychiatric changes after&#xD;
        surgery, such as daily large sputum production accompanied by cough, cleaning care of the air&#xD;
        incision, fatigue, and sleep disturbances. In patients with laryngeal cancer, large amounts&#xD;
        of secretions can cause frequent coughing, even wheezing, and coughing can exacerbate the&#xD;
        degree of postoperative pain. Some patients do not actively exclude secretions due to pain,&#xD;
        and the formation of sputum plugs causes lung inflammation, which is not conducive to&#xD;
        postoperative recovery. In addition, the inability to verbalize after laryngeal cancer&#xD;
        surgery puts patients in a state of anxiety, which increases the degree of postoperative&#xD;
        pain. Good postoperative pain management is beneficial to shorten the length of hospital stay&#xD;
        and reduce mortality. Sufentanil is most commonly used for postoperative analgesia and has&#xD;
        good analgesic effect, but there are some adverse effects, such as dizziness, nausea and&#xD;
        vomiting, urinary retention, skin itching, respiratory depression, etc. As a new type of&#xD;
        analgesic, dezocine has been widely used in clinical practice with few adverse reactions to&#xD;
        the respiratory and circulatory system, and its application to postoperative analgesia can&#xD;
        significantly improve the immune activity. At present, there are not many studies on&#xD;
        continuous analgesia of dezocine, mostly single-dose analgesia studies, this study for&#xD;
        different doses of dezocine for the postoperative analgesic effect of laryngeal cancer&#xD;
        patients, compared with the current classic opioid analgesics, to provide a new scheme for&#xD;
        clinical medication.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Completed</overall_status>
    <start_date type="Actual">February 10, 2022</start_date>
    <completion_date type="Actual">January 30, 2023</completion_date>
    <primary_completion_date type="Actual">January 14, 2023</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Crossover Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>total</measure>
      <time_frame>from the end of the surgery to 48 hours after surgery</time_frame>
      <description>no pain =0, mild pain =1-3, moderate pain =4-6, and severe pain =7-10</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>24 hours amount of drug</measure>
      <time_frame>From the time of use postoperative analgesic to the time of 24 hours after the surgery</time_frame>
      <description>the volume of postoperative analgesic in 24 hours after the surgery</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>48 hours pressing times of Patient-controlled Analgesia</measure>
      <time_frame>From the time of use postoperative analgesic to the time of 48 hours after the surgery</time_frame>
      <description>the times of press analgesia pump in 24 hours after the surgery</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Visual Analogue Scale</measure>
      <time_frame>at the time of 6 hours after the surgery</time_frame>
      <description>no pain =0, mild pain =1-3, moderate pain =4-6, and severe pain =7-10</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Visual Analogue Scale</measure>
      <time_frame>at the time of 12 hours after the surgery</time_frame>
      <description>no pain =0, mild pain =1-3, moderate pain =4-6, and severe pain =7-10</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Visual Analogue Scale</measure>
      <time_frame>at the time of 24 hours after the surgery</time_frame>
      <description>no pain =0, mild pain =1-3, moderate pain =4-6, and severe pain =7-10</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Visual Analogue Scale</measure>
      <time_frame>at the time of 48 hours after the surgery</time_frame>
      <description>no pain =0, mild pain =1-3, moderate pain =4-6, and severe pain =7-10</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>the incidence of nausea</measure>
      <time_frame>from the time when patients use postoperative analgesic to the time when patients stop to use postoperative analgesic, assessed up to 48 hours</time_frame>
      <description>the incidence of nausea</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>the incidence of vomiting</measure>
      <time_frame>from the time when patients use postoperative analgesic to the time when patients stop to use postoperative analgesic, assessed up to 48 hours</time_frame>
      <description>the incidence of vomiting</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>the incidence of dizziness</measure>
      <time_frame>from the time when patients use postoperative analgesic to the time when patients stop to use postoperative analgesic, assessed up to 48 hours</time_frame>
      <description>the incidence of dizziness</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>the incidence of urinary</measure>
      <time_frame>from the time when patients use postoperative analgesic to the time when patients stop to use postoperative analgesic, assessed up to 48 hours</time_frame>
      <description>the incidence of urinary</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>the incidence of respiratory depression</measure>
      <time_frame>from the time when patients use postoperative analgesic to the time when patients stop to use postoperative analgesic, assessed up to 48 hours</time_frame>
      <description>the incidence of respiratory depression</description>
    </secondary_outcome>
    <number_of_arms>3</number_of_arms>
    <enrollment type="Actual">129</enrollment>
    <condition>Patient-controlled Analgesia</condition>
    <arm_group>
      <arm_group_label>group S</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>sufentanil 2μg/kg + flurbiprofen 250mg+granisetron 6mg</description>
    </arm_group>
    <arm_group>
      <arm_group_label>group D1</arm_group_label>
      <arm_group_type>Active Comparator</arm_group_type>
      <description>dezocine 0.5mg/kg + flurbiprofen 250mg+granisetron 6mg</description>
    </arm_group>
    <arm_group>
      <arm_group_label>group D2</arm_group_label>
      <arm_group_type>Active Comparator</arm_group_type>
      <description>dezocine 0.6mg/kg + flurbiprofen 250mg+granisetron 6mg</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Dezocine</intervention_name>
      <description>dezocine for patient-controlled analgesia</description>
      <arm_group_label>group D1</arm_group_label>
      <arm_group_label>group D2</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Sufentanil injection</intervention_name>
      <description>sufentanil for patient-controlled analgesia</description>
      <arm_group_label>group S</arm_group_label>
      <other_name>sufentanil</other_name>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Flurbiprofen</intervention_name>
      <description>Flurbiprofen for patient-controlled analgesia</description>
      <arm_group_label>group D1</arm_group_label>
      <arm_group_label>group D2</arm_group_label>
      <arm_group_label>group S</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Granisetron Injection</intervention_name>
      <description>granisetron has antiemetic function.</description>
      <arm_group_label>group D1</arm_group_label>
      <arm_group_label>group D2</arm_group_label>
      <arm_group_label>group S</arm_group_label>
      <other_name>granisetron</other_name>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Patients who underwent elective partial laryngectomy&#xD;
  &#xD;
            -  American society of Anesthesiologists (ASA) physical status classification :Ⅰ~Ⅱ&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  chronic pain&#xD;
  &#xD;
            -  long-term use of analgesics&#xD;
  &#xD;
            -  allergy to perioperative medications&#xD;
  &#xD;
            -  previous postoperative nausea and vomiting&#xD;
        </textblock>
      </criteria>
      <gender>Female</gender>
      <minimum_age>N/A</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Jie Li</last_name>
      <role>Study Chair</role>
      <affiliation>Fudan University</affiliation>
    </overall_official>
    <location>
      <facility>
        <name>Fudan University</name>
        <address>
          <city>Shanghai</city>
          <state>Shanghai</state>
          <zip>200031</zip>
          <country>China</country>
        </address>
      </facility>
    </location>
    <location_countries>
      <country>China</country>
    </location_countries>
    <reference>
      <citation>Budliger H, Prader A, Morscher E, Fendel H. [Round table discussion on bone age]. Radiologe. 1971 Aug;11(8):296-9. No abstract available. German.</citation>
      <PMID>4329172</PMID>
    </reference>
    <reference>
      <citation>Perry F, Parker RK, White PF, Clifford PA. Role of psychological factors in postoperative pain control and recovery with patient-controlled analgesia. Clin J Pain. 1994 Mar;10(1):57-63; discussion 82-5. doi: 10.1097/00002508-199403000-00008.</citation>
      <PMID>8193445</PMID>
    </reference>
    <reference>
      <citation>O'Brien JJ, Benfield P. Dezocine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1989 Aug;38(2):226-48. doi: 10.2165/00003495-198938020-00005.</citation>
      <PMID>2670517</PMID>
    </reference>
    <reference>
      <citation>Wang YX, Mao XF, Li TF, Gong N, Zhang MZ. Dezocine exhibits antihypersensitivity activities in neuropathy through spinal mu-opioid receptor activation and norepinephrine reuptake inhibition. Sci Rep. 2017 Feb 23;7:43137. doi: 10.1038/srep43137.</citation>
      <PMID>28230181</PMID>
    </reference>
    <reference>
      <citation>Gharagozlou P, Demirci H, Clark JD, Lameh J. Activation profiles of opioid ligands in HEK cells expressing delta opioid receptors. BMC Neurosci. 2002 Nov 18;3:19. doi: 10.1186/1471-2202-3-19. Epub 2002 Nov 18.</citation>
      <PMID>12437765</PMID>
    </reference>
    <reference>
      <citation>Liu R, Huang XP, Yeliseev A, Xi J, Roth BL. Novel molecular targets of dezocine and their clinical implications. Anesthesiology. 2014 Mar;120(3):714-23. doi: 10.1097/ALN.0000000000000076.</citation>
      <PMID>24263237</PMID>
    </reference>
    <reference>
      <citation>Bian X, Zhou R, Yang Y, Li P, Hang Y, Hu Y, Yang L, Wen D. Divergent Effect of Dezocine, Morphine and Sufentanil on Intestinal Motor Function in Rats. Int J Med Sci. 2015 Oct 15;12(11):848-52. doi: 10.7150/ijms.12616. eCollection 2015.</citation>
      <PMID>26640403</PMID>
    </reference>
    <reference>
      <citation>Zhou X, Zhang C, Wang M, Yu L, Yan M. Dezocine for Preventing Postoperative Pain: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2015 Aug 19;10(8):e0136091. doi: 10.1371/journal.pone.0136091. eCollection 2015.</citation>
      <PMID>26287536</PMID>
    </reference>
    <reference>
      <citation>Wang C, Li L, Shen B, Jiang H, Yuan L, Shi D, Zhu J, Guo X, Li H. A multicenter randomized double-blind prospective study of the postoperative patient controlled intravenous analgesia effects of dezocine in elderly patients. Int J Clin Exp Med. 2014 Mar 15;7(3):530-9. eCollection 2014.</citation>
      <PMID>24753745</PMID>
    </reference>
    <reference>
      <citation>Zhou L, Zhang Y, Sun H, Hu R, Wang J, Xu G. Effect of preemptive dezocine before general anesthesia on postoperative analgesia in patients undergoing laparoscopic cholecystectomy: A prospective observational study. Medicine (Baltimore). 2018 Sep;97(39):e12533. doi: 10.1097/MD.0000000000012533.</citation>
      <PMID>30278544</PMID>
    </reference>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>May 4, 2023</study_first_submitted>
    <study_first_submitted_qc>August 12, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 21, 2023</study_first_posted>
    <last_update_submitted>August 12, 2023</last_update_submitted>
    <last_update_submitted_qc>August 12, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 21, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>dezocine</keyword>
    <keyword>sufentanil</keyword>
    <keyword>laryngectomy</keyword>
    <keyword>patient-controlled analgesia</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Agnosia</mesh_term>
    </condition_browse>
    <intervention_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Flurbiprofen</mesh_term>
      <mesh_term>Sufentanil</mesh_term>
      <mesh_term>Dsuvia</mesh_term>
      <mesh_term>Dezocine</mesh_term>
      <mesh_term>Granisetron</mesh_term>
    </intervention_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06000137
  org study id: dezocine and sufentanil
  nct id: NCT06000137
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  Laryngeal cancer is one of the most common tumors in otolaryngology. In China, it accounts
        for 1-5% of all malignancies and has an incidence of 1.13 per 100,000. Surgical resection is
        the most important treatment for patients who are not candidates for chemoradiotherapy or
        refuse chemoradiotherapy. The types of surgery include total and partial laryngectomy.
        Patients with laryngeal cancer often face multiple physical and psychiatric changes after
        surgery, such as daily large sputum production accompanied by cough, cleaning care of the air
        incision, fatigue, and sleep disturbances. Some patients do not actively exclude secretions
        due to pain, and the formation of sputum plugs causes lung inflammation, which is not
        conducive to postoperative recovery. Good postoperative pain management is beneficial to
        shorten the length of hospital stay and reduce mortality. Sufentanil is most commonly used
        for postoperative analgesia and has good analgesic effect, but there are some adverse
        effects, such as dizziness, nausea and vomiting, urinary retention, skin itching, respiratory
        depression, etc. As a new type of analgesic, dezocine has been widely used in clinical
        practice with few adverse reactions to the respiratory and circulatory system, and its
        application to postoperative analgesia can significantly improve the immune activity. At
        present, there are not many studies on continuous analgesia of dezocine, mostly single-dose
        analgesia studies, this study for different doses of dezocine for the postoperative analgesic
        effect of laryngeal cancer patients, compared with the current classic opioid analgesics, to
        provide a new scheme for clinical medication.
  Laryngeal cancer is one of the most common tumors in otolaryngology. In China, it accounts
        for 1-5% of all malignancies and has an incidence of 1.13 per 100,000. Surgical resection is
        the most important treatment for patients who are not candidates for chemoradiotherapy or
        refuse chemoradiotherapy. The types of surgery include total and partial laryngectomy.
        Patients with laryngeal cancer often face multiple physical and psychiatric changes after
        surgery, such as daily large sputum production accompanied by cough, cleaning care of the air
        incision, fatigue, and sleep disturbances. In patients with laryngeal cancer, large amounts
        of secretions can cause frequent coughing, even wheezing, and coughing can exacerbate the
        degree of postoperative pain. Some patients do not actively exclude secretions due to pain,
        and the formation of sputum plugs causes lung inflammation, which is not conducive to
        postoperative recovery. In addition, the inability to verbalize after laryngeal cancer
        surgery puts patients in a state of anxiety, which increases the degree of postoperative
        pain. Good postoperative pain management is beneficial to shorten the length of hospital stay
        and reduce mortality. Sufentanil is most commonly used for postoperative analgesia and has
        good analgesic effect, but there are some adverse effects, such as dizziness, nausea and
        vomiting, urinary retention, skin itching, respiratory depression, etc. As a new type of
        analgesic, dezocine has been widely used in clinical practice with few adverse reactions to
        the respiratory and circulatory system, and its application to postoperative analgesia can
        significantly improve the immune activity. At present, there are not many studies on
        continuous analgesia of dezocine, mostly single-dose analgesia studies, this study for
        different doses of dezocine for the postoperative analgesic effect of laryngeal cancer
        patients, compared with the current classic opioid analgesics, to provide a new scheme for
        clinical medication.
  allocation: Randomized
  intervention model: Crossover Assignment
  primary purpose: Treatment
  masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  measure: total
  time frame: from the end of the surgery to 48 hours after surgery
  description: no pain =0, mild pain =1-3, moderate pain =4-6, and severe pain =7-10
  measure: 24 hours amount of drug
  time frame: From the time of use postoperative analgesic to the time of 24 hours after the surgery
  description: the volume of postoperative analgesic in 24 hours after the surgery
  measure: 48 hours pressing times of Patient-controlled Analgesia
  time frame: From the time of use postoperative analgesic to the time of 48 hours after the surgery
  description: the times of press analgesia pump in 24 hours after the surgery
  measure: Visual Analogue Scale
  time frame: at the time of 6 hours after the surgery
  description: no pain =0, mild pain =1-3, moderate pain =4-6, and severe pain =7-10
  measure: Visual Analogue Scale
  time frame: at the time of 12 hours after the surgery
  description: no pain =0, mild pain =1-3, moderate pain =4-6, and severe pain =7-10
  measure: Visual Analogue Scale
  time frame: at the time of 24 hours after the surgery
  description: no pain =0, mild pain =1-3, moderate pain =4-6, and severe pain =7-10
  measure: Visual Analogue Scale
  time frame: at the time of 48 hours after the surgery
  description: no pain =0, mild pain =1-3, moderate pain =4-6, and severe pain =7-10
  measure: the incidence of nausea
  time frame: from the time when patients use postoperative analgesic to the time when patients stop to use postoperative analgesic, assessed up to 48 hours
  description: the incidence of nausea
  measure: the incidence of vomiting
  time frame: from the time when patients use postoperative analgesic to the time when patients stop to use postoperative analgesic, assessed up to 48 hours
  description: the incidence of vomiting
  measure: the incidence of dizziness
  time frame: from the time when patients use postoperative analgesic to the time when patients stop to use postoperative analgesic, assessed up to 48 hours
  description: the incidence of dizziness
  measure: the incidence of urinary
  time frame: from the time when patients use postoperative analgesic to the time when patients stop to use postoperative analgesic, assessed up to 48 hours
  description: the incidence of urinary
  measure: the incidence of respiratory depression
  time frame: from the time when patients use postoperative analgesic to the time when patients stop to use postoperative analgesic, assessed up to 48 hours
  description: the incidence of respiratory depression
  arm group label: group S
  arm group type: Experimental
  description: sufentanil 2μg/kg + flurbiprofen 250mg+granisetron 6mg
  arm group label: group D1
  arm group type: Active Comparator
  description: dezocine 0.5mg/kg + flurbiprofen 250mg+granisetron 6mg
  arm group label: group D2
  arm group type: Active Comparator
  description: dezocine 0.6mg/kg + flurbiprofen 250mg+granisetron 6mg
  intervention type: Drug
  intervention name: Dezocine
  description: dezocine for patient-controlled analgesia
  arm group label: group D1
  arm group label: group D2
  intervention type: Drug
  intervention name: Sufentanil injection
  description: sufentanil for patient-controlled analgesia
  arm group label: group S
  other name: sufentanil
  intervention type: Drug
  intervention name: Flurbiprofen
  description: Flurbiprofen for patient-controlled analgesia
  arm group label: group D1
  arm group label: group D2
  arm group label: group S
  intervention type: Drug
  intervention name: Granisetron Injection
  description: granisetron has antiemetic function.
  arm group label: group D1
  arm group label: group D2
  arm group label: group S
  other name: granisetron
  criteria: 
  gender: Female
  minimum age: N/A
  maximum age: N/A
  healthy volunteers: No
  last name: Jie Li
  role: Study Chair
  affiliation: Fudan University
  facility: 
  country: China
  citation: Budliger H, Prader A, Morscher E, Fendel H. [Round table discussion on bone age]. Radiologe. 1971 Aug;11(8):296-9. No abstract available. German.
  PMID: 4329172
  citation: Perry F, Parker RK, White PF, Clifford PA. Role of psychological factors in postoperative pain control and recovery with patient-controlled analgesia. Clin J Pain. 1994 Mar;10(1):57-63; discussion 82-5. doi: 10.1097/00002508-199403000-00008.
  PMID: 8193445
  citation: O'Brien JJ, Benfield P. Dezocine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1989 Aug;38(2):226-48. doi: 10.2165/00003495-198938020-00005.
  PMID: 2670517
  citation: Wang YX, Mao XF, Li TF, Gong N, Zhang MZ. Dezocine exhibits antihypersensitivity activities in neuropathy through spinal mu-opioid receptor activation and norepinephrine reuptake inhibition. Sci Rep. 2017 Feb 23;7:43137. doi: 10.1038/srep43137.
  PMID: 28230181
  citation: Gharagozlou P, Demirci H, Clark JD, Lameh J. Activation profiles of opioid ligands in HEK cells expressing delta opioid receptors. BMC Neurosci. 2002 Nov 18;3:19. doi: 10.1186/1471-2202-3-19. Epub 2002 Nov 18.
  PMID: 12437765
  citation: Liu R, Huang XP, Yeliseev A, Xi J, Roth BL. Novel molecular targets of dezocine and their clinical implications. Anesthesiology. 2014 Mar;120(3):714-23. doi: 10.1097/ALN.0000000000000076.
  PMID: 24263237
  citation: Bian X, Zhou R, Yang Y, Li P, Hang Y, Hu Y, Yang L, Wen D. Divergent Effect of Dezocine, Morphine and Sufentanil on Intestinal Motor Function in Rats. Int J Med Sci. 2015 Oct 15;12(11):848-52. doi: 10.7150/ijms.12616. eCollection 2015.
  PMID: 26640403
  citation: Zhou X, Zhang C, Wang M, Yu L, Yan M. Dezocine for Preventing Postoperative Pain: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2015 Aug 19;10(8):e0136091. doi: 10.1371/journal.pone.0136091. eCollection 2015.
  PMID: 26287536
  citation: Wang C, Li L, Shen B, Jiang H, Yuan L, Shi D, Zhu J, Guo X, Li H. A multicenter randomized double-blind prospective study of the postoperative patient controlled intravenous analgesia effects of dezocine in elderly patients. Int J Clin Exp Med. 2014 Mar 15;7(3):530-9. eCollection 2014.
  PMID: 24753745
  citation: Zhou L, Zhang Y, Sun H, Hu R, Wang J, Xu G. Effect of preemptive dezocine before general anesthesia on postoperative analgesia in patients undergoing laparoscopic cholecystectomy: A prospective observational study. Medicine (Baltimore). 2018 Sep;97(39):e12533. doi: 10.1097/MD.0000000000012533.
  PMID: 30278544
  responsible party type: Sponsor
  mesh term: Agnosia
  mesh term: Flurbiprofen
  mesh term: Sufentanil
  mesh term: Dsuvia
  mesh term: Dezocine
  mesh term: Granisetron
  sharing ipd: No